Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mDC3/8 Vaccine + Pembrolizumab in Advanced Melanoma
NCT03092453Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- May 2017
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in melanoma, sponsored by University of Pennsylvania. Primary endpoints: Immune Response Measuring Increased Numbers of Peptide Specific T Cells and Safety and Tolerability of the Mature Dendritic Cell Vaccine. Started May 2017; status: completed.
02
Conditions
melanoma
Beyond the preview
Go deeper on NCT03092453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03092453.